July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
The 548-person U.S. study found that chronic hepatitis C infection occurred among an identical number of people who received the experimental vaccine compared to people who received a placebo.
June 13, 2019: Integrated stepped alcohol treatment in HIV clinics; cytokines, inflammation, and heart risk; impact of CCR5 gene editing on lifespan; the costs of "test and treat" for hepatitis C.
Authors of a literature review note the high prevalence of liver disease among people with HIV and recommend a step-by-step approach to management.
When people living with HIV are admitted to a hospital, they may not be able to bring their medications with them, and could be prescribed new medication by a doctor who doesn't understand their complete medical history.
Two models, one from Washington State and another from Los Angeles County, can be duplicated elsewhere to get people into care, experts say.
"Providing HCV treatment alone while neglecting to concurrently address the social determinants of health will do little to improve the health outcomes of the majority of individuals with chronic HCV," the study authors wrote.
The data also reveals an estimated 2.3 million people living with HCV infection in the U.S. between 2013 and 2016, with a high burden in the West and in some Appalachian states.
Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.
Prior studies have indicated that hepatitis C direct-acting antivirals reduce the risk of hepatocellular carcinoma, but this is the first large prospective study to compare outcomes among treated and untreated patients.